MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.
Read more at prnewswire.comAlterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)